- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Placebo to ertugliflozin 15 mg, Placebo to ertugliflozin 5 mg, Insulin, Metformin
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 985–1008
of 4,796
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
- Interventions
- HLX17, US-sourced Keytruda®
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 12
- States / cities
- Glendale, California • Los Alamitos, California • Los Angeles, California + 8 more
- Conditions
- Leprosy
- Interventions
- LEP-F1 + GLA-SE
- Biological
- Lead sponsor
- Access to Advanced Health Institute (AAHI)
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Evidence of Liver Transplantation, Arterial Occlusive Diseases, Hypertension, Pregnancy, High Risk, Pregnancy
- Interventions
- GE LOGIQ E9 Ultrasound System
- Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Visual Acuity
- Interventions
- JJVC Fitting Guides
- Device
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Zilovertamab vedotin
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 19
- States / cities
- Orange, California • Whittier, California • Washington D.C., District of Columbia + 16 more
- Conditions
- Schizophrenia
- Interventions
- SEP-363856 50mg, SEP-363856 75mg, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Anaheim, California • Bellflower, California + 13 more
- Conditions
- Dry Eye Disease
- Interventions
- 0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL), 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL), 2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL), Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Andover, Massachusetts • Nashville, Tennessee
- Conditions
- Arthritis, Inflammatory
- Interventions
- Synovasure® RISC™ Panel
- Diagnostic Test
- Lead sponsor
- Zimmer Biomet
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 1,000 participants
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Friedreich Ataxia, Rare Diseases
- Interventions
- Geneticlly confirmed disease causing FXN mutatuion, Healthy Control
- Other
- Lead sponsor
- Friedreich's Ataxia Research Alliance
- Other
- Eligibility
- 4 Years to 21 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Philadelphia, Pennsylvania • Memphis, Tennessee
- Conditions
- Acute Kidney Injury
- Interventions
- RMC-035, Placebo
- Drug
- Lead sponsor
- Guard Therapeutics AB
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Fort Wayne, Indiana • Lincoln, Nebraska • Rochester, New York + 5 more
- Conditions
- Acute Pain, Surgery
- Interventions
- NeuroIDgenetix Test Panel
- Genetic
- Lead sponsor
- AltheaDx
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Hemophilia A
- Interventions
- Emicizumab, rFVIIa, aPCC
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
- Conditions
- Stroke
- Interventions
- CVA-Flow
- Device
- Lead sponsor
- Cvaid Medical
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Community-acquired Pneumonia
- Interventions
- AON-D21, Placebo
- Drug
- Lead sponsor
- Aptarion Biotech AG
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Tuberculosis
- Interventions
- T-Cell SelectTM Kit
- Diagnostic Test
- Lead sponsor
- Oxford Immunotec
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 680 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Fall River, Massachusetts • Columbus, Ohio • Brownsville, Texas
- Conditions
- Deep Vein Thrombosis, Venous Thrombosis
- Interventions
- Deep Vein Thrombosis (DVT) Cuff
- Device
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
- Interventions
- Esomeprazole (Nexium)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 1 Year to 11 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 24
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Wilmington, Delaware + 21 more
- Conditions
- ANCA-Associated Vasculitis
- Interventions
- Avacopan, Prednisone, Cyclophosphamide, Rituximab, Azathioprine
- Drug · Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 41
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more
- Conditions
- NGLY1 Deficiency
- Interventions
- Not listed
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Deglutition Disorder, High Risk Pregnancy
- Interventions
- Not listed
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Herpesviridae Infection, HTLV-I Infection, Multiple Sclerosis, Tropical Spastic Paraparesis, Vasculitis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1976 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- IGIV3I Grifols 10%
- Biological
- Lead sponsor
- Grifols Biologicals, LLC
- Industry
- Eligibility
- 3 Years to 70 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 26 more
- Conditions
- Tonsillitis, Pharyngitis
- Interventions
- Telithromycin, Penicillin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey